Highlighted research articles

IF 11.5 Q1 HEMATOLOGY Blood Cancer Discovery Pub Date : 2023-09-01 DOI:10.1158/2643-3230.bcd-4-5-iti

{"title":"Highlighted research articles","authors":"","doi":"10.1158/2643-3230.bcd-4-5-iti","DOIUrl":null,"url":null,"abstract":"In This Issue| September 01 2023 Highlighted research articles Author & Article Information Online ISSN: 2643-3249 Print ISSN: 2643-3230 ©2023 American Association for Cancer Research2023American Association for Cancer Research Blood Cancer Discov (2023) 4 (5): 337. https://doi.org/10.1158/2643-3230.BCD-4-5-ITI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 1 2023 Citation Highlighted research articles. Blood Cancer Discov 1 September 2023; 4 (5): 337. https://doi.org/10.1158/2643-3230.BCD-4-5-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Biomarkers predicting CAR T-cell (CAR T) therapy outcomes in myeloma remain to be established. In this prespecified analysis of the KarMMa trial, Paiva et al. show that persistent measurable residual disease (MRD) around the time of peak expansion correlates with primary resistance to idecabtagene vicleucel. Associations of outcomes with M-protein and circulating plasma cells over the 1-year course were distinct from their profiles following traditional myeloma treatments, highlighting the unique biological mechanism of CAR T therapy. The findings offer one of the first clinical guides to using biomarkers for tailoring salvage therapy following CAR T in myeloma. See article, p. 365. The hallmarks of cancer include deregulated cellular metabolism and epigenetic reprogramming. In this work, Toyoda et al. show that a viral oncogene encoded in human T-cell leukemia virus type 1 (HTLV-1), HTLV-1 bZIP factor (HBZ), upregulates TAp73 by its two molecular forms, HBZ RNA and HBZ protein, via... You do not currently have access to this content.","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2643-3230.bcd-4-5-iti","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In This Issue| September 01 2023 Highlighted research articles Author & Article Information Online ISSN: 2643-3249 Print ISSN: 2643-3230 ©2023 American Association for Cancer Research2023American Association for Cancer Research Blood Cancer Discov (2023) 4 (5): 337. https://doi.org/10.1158/2643-3230.BCD-4-5-ITI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 1 2023 Citation Highlighted research articles. Blood Cancer Discov 1 September 2023; 4 (5): 337. https://doi.org/10.1158/2643-3230.BCD-4-5-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Biomarkers predicting CAR T-cell (CAR T) therapy outcomes in myeloma remain to be established. In this prespecified analysis of the KarMMa trial, Paiva et al. show that persistent measurable residual disease (MRD) around the time of peak expansion correlates with primary resistance to idecabtagene vicleucel. Associations of outcomes with M-protein and circulating plasma cells over the 1-year course were distinct from their profiles following traditional myeloma treatments, highlighting the unique biological mechanism of CAR T therapy. The findings offer one of the first clinical guides to using biomarkers for tailoring salvage therapy following CAR T in myeloma. See article, p. 365. The hallmarks of cancer include deregulated cellular metabolism and epigenetic reprogramming. In this work, Toyoda et al. show that a viral oncogene encoded in human T-cell leukemia virus type 1 (HTLV-1), HTLV-1 bZIP factor (HBZ), upregulates TAp73 by its two molecular forms, HBZ RNA and HBZ protein, via... You do not currently have access to this content.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

重点研究文章

本期| 2023年9月1日重点研究文章作者与文章信息在线ISSN: 2643-3249印刷ISSN: 2643-3230©2023美国癌症研究协会2023美国癌症研究协会血癌发现(2023)4(5):337。https://doi.org/10.1158/2643-3230.BCD-4-5-ITI查看图标查看文章内容图表和表格视频音频补充数据同行评审共享图标共享Facebook Twitter LinkedIn电子邮件工具图标工具获得权限引用图标引用搜索网站文章版本图标版本记录版本2023年9月1日引用突出显示的研究文章。发现血癌2023年9月1日;4(5): 337。https://doi.org/10.1158/2643-3230.BCD-4-5-ITI下载引用文件:Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex工具栏搜索搜索下拉菜单工具栏搜索搜索输入搜索输入自动建议搜索高级搜索预测骨髓瘤CAR - T细胞(CAR - T)治疗结果的生物标志物仍有待建立。在这项预先指定的karma试验分析中，Paiva等人表明，在扩增高峰前后持续可测量的残留病(MRD)与对idecabtagene小粒核的初次耐药相关。在1年的治疗过程中，与m蛋白和循环浆细胞相关的结果与传统骨髓瘤治疗不同，这突出了CAR - T治疗的独特生物学机制。这一发现为骨髓瘤CAR - T治疗后使用生物标志物进行定制挽救治疗提供了首批临床指南之一。见文章，第365页。癌症的特征包括细胞代谢失控和表观遗传重编程。在这项工作中，Toyoda等人发现，人类t细胞白血病病毒1型(HTLV-1)中编码的一种病毒致癌基因HTLV-1 bZIP因子(HBZ)通过HBZ RNA和HBZ蛋白两种分子形式上调TAp73。您目前没有访问此内容的权限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.